Frankfurt - Delayed Quote EUR

Solvonis Therapeutics plc (J4I.F)

Compare
0.0005
0.0000
(0.00%)
As of 8:01:36 AM GMT+1. Market Open.
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
5/31/2021
5/31/2020
Total Revenue
587.0000
587.0000
542.0000
520.0000
330.0000
Cost of Revenue
329.0000
329.0000
242.0000
30.0000
46.0000
Gross Profit
258.0000
258.0000
300.0000
490.0000
284.0000
Operating Expense
2,468.0000
2,468.0000
2,991.0000
932.0000
748.0000
Operating Income
-2,210.0000
-2,210.0000
-2,691.0000
-442.0000
-464.0000
Net Non Operating Interest Income Expense
-3.0000
-3.0000
-4.0000
-7.0000
-72.0000
Pretax Income
-3,120.0000
-3,120.0000
-2,705.0000
-451.0000
-538.0000
Net Income Common Stockholders
-3,120.0000
-3,120.0000
-2,705.0000
-451.0000
-538.0000
Diluted NI Available to Com Stockholders
-3,120.0000
-3,120.0000
-2,705.0000
-451.0000
-538.0000
Basic EPS
-0.03
-0.03
-0.03
-0.00
-0.01
Diluted EPS
-0.03
-0.03
-0.03
-0.00
-0.01
Basic Average Shares
104,057.2990
104,057.2990
103,589.4790
104,097.2990
104,097.2990
Diluted Average Shares
104,057.2990
104,057.2990
103,589.4790
104,097.2990
104,097.2990
Total Operating Income as Reported
-3,117.0000
-3,117.0000
-2,701.0000
-444.0000
-352.0000
Total Expenses
2,797.0000
2,797.0000
3,233.0000
962.0000
794.0000
Net Income from Continuing & Discontinued Operation
-3,120.0000
-3,120.0000
-2,705.0000
-451.0000
-538.0000
Normalized Income
-2,282.0000
-2,282.0000
-2,705.0000
-451.0000
-538.0000
Interest Expense
3.0000
3.0000
4.0000
7.0000
72.0000
Net Interest Income
-3.0000
-3.0000
-4.0000
-7.0000
-72.0000
EBIT
-3,117.0000
-3,117.0000
-2,701.0000
-444.0000
-466.0000
EBITDA
-2,938.0000
-2,938.0000
-2,588.0000
-335.0000
-352.0000
Reconciled Cost of Revenue
329.0000
329.0000
242.0000
30.0000
46.0000
Reconciled Depreciation
177.0000
177.0000
113.0000
109.0000
114.0000
Net Income from Continuing Operation Net Minority Interest
-3,120.0000
-3,120.0000
-2,705.0000
-451.0000
-538.0000
Total Unusual Items Excluding Goodwill
-838.0000
-838.0000
--
--
--
Total Unusual Items
-838.0000
-838.0000
--
--
--
Normalized EBITDA
-2,100.0000
-2,100.0000
-2,588.0000
-335.0000
-352.0000
5/31/2020 - 1/19/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade